92 related articles for article (PubMed ID: 6235326)
1. A trial of autologous plasma perfusion over protein A in patients with breast cancer.
Fer MF; Beman J; Stevenson HC; Maluish A; Moratz C; Delawter T; Foon K; Herberman RB; Oldham RK; Terman DS
J Biol Response Mod; 1984; 3(3):352-8. PubMed ID: 6235326
[No Abstract] [Full Text] [Related]
2. Ultrastructural changes in breast tumors of patients following treatment with plasma perfused over immobilized protein A.
Daskal Y; Mattioli CA; Terman DS
J Biol Response Mod; 1984; 3(3):247-54. PubMed ID: 6379108
[No Abstract] [Full Text] [Related]
3. Staphylococcal protein A immunoadsorptive column induces mitogenicity in perfused plasma.
Bertram JH; Hengst JC; Mitchell MS
J Biol Response Mod; 1984; 3(3):235-40. PubMed ID: 6379107
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial of plasma perfusion over immobilized staphylococcal protein A in metastatic breast cancer.
Ventura GJ; Buzdar AU; Kau S; Lichtiger B; Hortobagyi GN
Cancer Treat Rep; 1987 Apr; 71(4):411-3. PubMed ID: 3548958
[TBL] [Abstract][Full Text] [Related]
5. [Quantitative and functional response of a lymphatic subpopulation during adjuvant intermittent chemo-immunotherapy in breast cancer].
Betzler M; Flad HD; Huget R; Schreml W; Schlag P; Herfarth C
Chir Forum Exp Klin Forsch; 1978; (1978):227-30. PubMed ID: 313321
[TBL] [Abstract][Full Text] [Related]
6. Experience with Staphylococcus aureus and protein A in the treatment of canine malignancies.
Bowles CA; Messerschmidt G; Deisseroth AB
J Biol Response Mod; 1984; 3(3):260-5. PubMed ID: 6379110
[No Abstract] [Full Text] [Related]
7. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer.
Visonneau S; Cesano A; Porter DL; Luger SL; Schuchter L; Kamoun M; Torosian MH; Duffy K; Sickles C; Stadtmauer EA; Santoli D
Clin Cancer Res; 2000 May; 6(5):1744-54. PubMed ID: 10815893
[TBL] [Abstract][Full Text] [Related]
8. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period.
Lister J; Rybka WB; Donnenberg AD; deMagalhaes-Silverman M; Pincus SM; Bloom EJ; Elder EM; Ball ED; Whiteside TL
Clin Cancer Res; 1995 Jun; 1(6):607-14. PubMed ID: 9816022
[TBL] [Abstract][Full Text] [Related]
9. Clinical response to protein a-treated plasma infusions and in vitro correlation.
MacKintosh FR; Bennett K; Hall SW
J Biol Response Mod; 1984; 3(3):336-40. PubMed ID: 6379117
[No Abstract] [Full Text] [Related]
10. Does perfusion with treated plasma cure cancer?
Hellström KE; Hellström I
N Engl J Med; 1981 Nov; 305(20):1215-6. PubMed ID: 6270555
[No Abstract] [Full Text] [Related]
11. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
12. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.
Burns LJ; Weisdorf DJ; DeFor TE; Vesole DH; Repka TL; Blazar BR; Burger SR; Panoskaltsis-Mortari A; Keever-Taylor CA; Zhang MJ; Miller JS
Bone Marrow Transplant; 2003 Jul; 32(2):177-86. PubMed ID: 12838283
[TBL] [Abstract][Full Text] [Related]
13. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
14. Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro.
Delirezh N; Moazzeni SM; Shokri F; Shokrgozar MA; Atri M; Kokhaei P
Cell Immunol; 2009; 257(1-2):23-31. PubMed ID: 19306994
[TBL] [Abstract][Full Text] [Related]
15. Clinical trials with Staphylococcus aureus and protein A in the treatment of malignant disease.
Messerschmidt GL; Bowles CA; Henry DH; Deisseroth AB
J Biol Response Mod; 1984; 3(3):325-9. PubMed ID: 6379115
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer.
Goedegebuure PS; Douville CC; Doherty JM; Linehan DC; Lee KY; Ganguly EK; Eberlein TJ
Cell Immunol; 1997 Feb; 175(2):150-6. PubMed ID: 9023420
[TBL] [Abstract][Full Text] [Related]
17. Staphylococcal protein A in neoplastic disease.
Terman DS
J Biol Response Mod; 1984; 3(3):316-24. PubMed ID: 6379114
[No Abstract] [Full Text] [Related]
18. [Autologous tumor specific immunotherapy of refractory cancers with ex vivo-generated T cells stimulated by autologous tumor cell].
Toh U; Yamana H; Kido K; Mine T; Fujii T; Horiuchi H; Sasatomi T; Ishibashi N; Yutani S; Fujita H; Shirouzu K
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1566-70. PubMed ID: 14619465
[TBL] [Abstract][Full Text] [Related]
19. Immune responses to guided imagery during breast cancer treatment.
Lengacher CA; Bennett MP; Gonzalez L; Gilvary D; Cox CE; Cantor A; Jacobsen PB; Yang C; Djeu J
Biol Res Nurs; 2008 Jan; 9(3):205-14. PubMed ID: 18077773
[TBL] [Abstract][Full Text] [Related]
20. FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function.
Chen W; Chan AS; Dawson AJ; Liang X; Blazar BR; Miller JS
Biol Blood Marrow Transplant; 2005 Jan; 11(1):23-34. PubMed ID: 15625541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
